On Jun 27, 2018 “Buy” Rating Received Ascendis Pharma (NASDAQ:ASND) at Stifel Nicolaus with $85 Target.

June 27, 2018 - By Matthew Medley

What Price Target Has Stifel Nicolaus Given Ascendis Pharma (NASDAQ:ASND)

upside potential of 26.17 % on Ascendis Pharma (NASDAQ:ASND) gives $85 price target given by Equity research analysts at Stifel Nicolaus. Also on Tuesday, 26 June coverage has started by broker on the $2.80 billion market cap company.

Ascendis Pharma A/S (NASDAQ:ASND) Ratings Coverage

A total of 6 analysts rate Ascendis Pharma (NASDAQ:ASND) as follows: 5 “Buy”, 1 “Hold” and 0 “Sell”. Тherefore 83% are bullish. (NASDAQ:ASND) has 14 ratings reports on Jun 27, 2018 according to StockzIntelligence. The stock rating was maintained by Wedbush with “Buy” on Monday, February 26. On Wednesday, January 17 the firm has “Buy” rating by J.P. Morgan given. On Tuesday, February 6 the firm has “Buy” rating by Wedbush given. On Thursday, January 25 Bank of America maintained the shares of ASND in report with “Buy” rating. The company rating was maintained by Wedbush on Wednesday, April 4. The stock rating was maintained by Credit Suisse with “Outperform” on Tuesday, March 20. On Monday, May 14 the company was maintained by J.P. Morgan. On Thursday, February 22 the stock of Ascendis Pharma A/S (NASDAQ:ASND) earned “Buy” rating by Credit Suisse. On Friday, January 5 Wedbush maintained Ascendis Pharma A/S (NASDAQ:ASND) with “Buy” rating. On Tuesday, May 15 the stock of Ascendis Pharma A/S (NASDAQ:ASND) has “Buy” rating given by Wedbush.

Ticker’s shares touched $67.37 during the last trading session after 2.25% change.Ascendis Pharma A/S has 182,366 shares volume, 48.85% up from normal. ASND is uptrending and has moved 178.35% since June 27, 2017. ASND outperformed by 165.78% the S&P500.

On August, 17 is expected Ascendis Pharma A/S (NASDAQ:ASND)’s earnings report, according to Zacks. Analysts expect change of 7.69 % or $0.08 from previous year’s $-1.04 earnings per share compared to current’s $-0.96 earnings per share. After $-1.31 earnings per share was announced previous quarter, analysts now see EPS growth of -26.72 % for Ascendis Pharma A/S.

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs.The firm is worth $2.80 billion. The firm develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.Last it reported negative earnings. It also has strategic collaborations with Sanofi to develop TransCon Peptides for the treatment of diabetes; and Genentech and Roche to develop TransCon anti-vascular endothelial growth factor , a compound to support injection of anti-VEGF in ophthalmology.

For more Ascendis Pharma A/S (NASDAQ:ASND) news announced briefly go to: Benzinga.com, Nasdaq.com, Nasdaq.com, Globenewswire.com or 247Wallst.com. The titles are as follows: “Benzinga’s Top Upgrades, Downgrades For June 26, 2018” announced on June 26, 2018, “Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon PTH as Treatment for Hypoparathyroidism” on June 06, 2018, “Investor Expectations to Drive Momentum within Gladstone Commercial, Old Line Bancshares, Randgold Resources …” with a publish date: June 06, 2018, “Ascendis Pharma A/S Reports First Quarter 2018 Financial Results” and the last “Biopharma Companies to Watch This Week” with publication date: June 24, 2018.

Ascendis Pharma A/S (NASDAQ:ASND) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.